Concert Pharmaceuticals Inc

Company Profile

Concert Pharmaceuticals Inc had its IPO on 2014-02-13 under the ticker symbol CNCE.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. Concert Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Concert Pharmaceuticals Inc opened at $5.88 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $5.6 - $5.95, and closed at $5.8.

This is a -1.86% slip from the previous day's closing price.

A total volume of 611,215 shares were traded at the close of the day’s session.

In the last one week, shares of Concert Pharmaceuticals Inc have slipped by -3.33%.

Concert Pharmaceuticals Inc's Key Ratios

Concert Pharmaceuticals Inc has a market cap of $0.278 billion, indicating a price to book ratio of 2.262 and a price to sales ratio of 8.53.

In the last 12-months Concert Pharmaceuticals Inc’s revenue was $0.033 billion with a gross profit of $-0.055 billion and an EBITDA of $-0.088 billion. The EBITDA ratio measures Concert Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Concert Pharmaceuticals Inc’s operating margin was -274.6% while its return on assets stood at -34.4% with a return of equity of -99.1%.

In Q2, Concert Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 23.5%.

Concert Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE

-

Trailing PE

-

PEG

0

Its diluted EPS in the last 12-months stands at $-2.71 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Concert Pharmaceuticals Inc’s profitability.

Concert Pharmaceuticals Inc stock is trading at a EV to sales ratio of 257.75 and a EV to EBITDA ratio of -1.24. Its price to sales ratio in the trailing 12-months stood at 8.53.

Concert Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

Concert Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Concert Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Concert Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Concert Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Concert Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$5.8

52-Week High

$7.37

52-Week Low

$2.57

Analyst Target Price

$17.2

Concert Pharmaceuticals Inc stock is currently trading at $5.8 per share. It touched a 52-week high of $7.37 and a 52-week low of $7.37. Analysts tracking the stock have a 12-month average target price of $17.2.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.